Dendritic cells (DCs) are pivotal regulators of immune responses, specialized in antigen presentation and bridging the gap between the innate and adaptive immune system. Due to these key features, DCs have become a pillar of the continuously growing field of cellular therapies. Here we review recent advances in good manufacturing practice strategies and their individual specificities in relation to DC production for clinical applications. These take into account both small-scale experimental approaches as well as automated systems for patient care.

中文翻译：

---

良好生产规范级树突细胞生成的最新进展

树突状细胞 (DC) 是免疫反应的关键调节剂，专门用于抗原呈递并弥合先天免疫系统和适应性免疫系统之间的差距。由于这些关键特征，DC 已成为不断发展的细胞疗法领域的支柱。在这里，我们回顾了良好生产实践策略的最新进展及其与临床应用 DC 生产相关的个体特异性。这些考虑到了小规模的实验方法以及用于患者护理的自动化系统。